9p loss, which includes the tumor suppressor CDKN2A, was associated with upregulation of translation initiation, mTOR and MYC signaling, consistent with loss of CDKN2A and MYC activation previously reported in ccRCC progression (Bailey et al., 2017). The gene discussed is MYC; the disease is nonpapillary renal cell carcinoma.